Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: MRK stock price vs AORT: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AORT's multiple
Needs AORT P/E.
Implied fair value · at MRK's multiple
Needs MRK P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Merck & Co., Inc. · implied price per share
Bear
$49.07
Base
$60.10
Bull
$74.45
ARTIVION, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Pfizer Inc.
MRK vs PFE
Johnson & Johnson
MRK vs JNJ
Eli Lilly and Company
MRK vs LLY
Bristol-Myers Squibb Company
MRK vs BMY
AbbVie Inc.
MRK vs ABBV
AMGEN INC
MRK vs AMGN
ABBOTT LABORATORIES
MRK vs ABT
BOSTON SCIENTIFIC CORP
MRK vs BSX
ZIMMER BIOMET HOLDINGS, INC.
MRK vs ZBH
TELEFLEX INC
MRK vs TFX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe MRK deserves a premium for its superior margins and scale, then hold or add selectively rather than chase the implied 614.4% upside, because MRK already trades near the top of its historical band and above the DCF range despite stronger fundamentals than AORT.
The comparison produces a very large apparent valuation gap: MRK trades at 17.9x P/E versus AORT at 127.8x, which mathematically drives the $930.11 implied price and 614.4% upside figure. However, that implied value is anchored to a relative multiple framework that looks distorted by AORT's much higher earnings multiple and much smaller earnings base.
Supporting Metrics
